NNC0480-0389 / Novo Nordisk  >>  Phase 1
Welcome,         Profile    Billing    Logout  

6 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
NNC0480-0389 / Novo Nordisk
NCT04878406: A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Japanese Men

Completed
1
24
Japan
NNC0480-0389, Placebo (NNC0480-0389), Semaglutide, Placebo (Semaglutide)
Novo Nordisk A/S
Healthy Volunteers Type 2 Diabetes
07/21
07/21
NCT05046873: A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People

Completed
1
16
Europe
Co-formulation NNC0480 0389+Semaglutide A 10/1 mg/mL, semaglutide 1.34 mg/mL (placebo), Semaglutide 1.34 mg/mL, NNC0480-0389 A 10 mg/mL
Novo Nordisk A/S
Diabetes Mellitus, Type 2
01/22
01/22
NCT04259801: First Research Study to Look at How Two Medicines, NNC0480-0389 and Semaglutide, Work Together in Healthy People, in People With High Body Weight and in People With Diabetes

Completed
1
152
Europe
NNC0480-0389, Semaglutide, Placebo (NNC0480-0389), Placebo (semaglutide)
Novo Nordisk A/S
Healthy Volunteers, Overweight, Obesity, Diabetes Mellitus, Type 2
03/22
03/22
NCT05015894: A Research Study Looking Into Blood Levels of the Medicine NNC0480-0389 in Participants With Reduced Kidney Function Compared to Participants With Normal Kidney Function

Completed
1
42
Europe
NNC0480-0389
Novo Nordisk A/S
Diabetes Mellitus, Type 2
08/22
08/22
NCT05153564: A Research Study Looking Into the Effect of Semaglutide and NNC0480 0389 on Blood Levels of a Birth Control Pill in Woman After Menopause

Completed
1
27
Europe
Semaglutide 1.34 mg/mL, Semaglutide 3.0 mg/mL, NNC0480-0389 10 mg/mL, NNC0480-0389 30 mg/mL, Microgynon®
Novo Nordisk A/S
Diabetes Mellitus, Type 2
08/22
09/22
NCT05498610: A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Chinese Men

Completed
1
24
RoW
NNC0480 0389, Semaglutide
Novo Nordisk A/S
Diabetes Mellitus, Type 2
10/22
10/22

Download Options